Newsmeme!
Discover News you didn't know existed
Scientists at Albert Einstein College of Medicine of Yeshiva University have devised a laboratory test for predicting whether microbicides against HIV are safe for human use. The researchers have also discovered why several supposedly "safe" microbicides made women more susceptible to HIV infection. The study appears today in the online version of the Journal of Infectious Diseases.
Questions and answers on Daily Bulletin stories from readers like you.
Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects. The class of immunosuppressive drugs known as calcineurin inhibitors (examples are cyclosporine and tacrolimus) can damage patients' kidneys and lead to high blood pressure, among other problems.
The inflammatory process in the brain of multiple sclerosis patients is triggered by their own immune system. However, there is one type of immune cells that seems to fight against the destructive progress - and might be used for therapeutic purposes in future.
Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced the start of a post-approval clinical ...
New research published in Journal of Infectious Diseases highlights a new lab test that better predicts microbicide safety. Research at Albert Einstein College of Medicine explains why several once-promising microbicides have failed.
Findings published by Monell Center scientists in the American Journal of Clinical Nutrition also indicate that variations in the genes that code for the proteins T1R1 and T1R3 correspond to individual variation in sensitivity to the perceived intensity of umami taste.
Researchers at Cellular Dynamics International (CDI) report the ability to generate pluripotent stem cells, which have the ability to generate all tissue types in the body, from very small volumes of ordinary human blood samples.
Kineta, Inc of Seattle and Airmid Incorporated of Redwood City, California jointly announce an agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid.
The doctor had barely pulled away the needle when a blister appeared on Tracey Berg-Fulton's abdomen: An experimental shot was revving up the 24-year-old's immune system -- part of a bold quest to create a vaccine-like therapy for diabetes. "If we're right, that is what's going to stop Type 1 diabetes," said Dr. David Finegold as he watched the blisters appear -- one to match each of four shots ...
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |